Clinical trial · Interventional
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Real-world Effectiveness of Adjuvant Octreotide Therapy in High Recurrence Risk Patients With Pancreatic Neuroendocrine Tumors
NCT06080204CI-TRIAL-00070590completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Adjuvant therapy in pancreatic neuroendocrine tumors (pNETs) after radical resection lacks evidence-based data and is controversial. Real-world data were clustered to validate whether the long-acting octreotide is a potential candidate for adjuvant therapy in high recurrence risk G2 pNET patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Neuroendocrine Tumor G2 | Pancreatic Neuroendocrine Tumor G2 | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Octreotide LAR | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Octreotide group
- description
- Patients in the octreotide group received octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months, with the start of clinical intervention following surgery.
- interventionNames
- Drug: Octreotide LAR
- type
- NO_INTERVENTION
- label
- Control group
- description
- No adjuvant therapy after surgery.
Primary outcomes (1)
- measure
- Disease-free survival time
- timeFrame
- From the date of surgery to the date of distant metastasis or recurrence or death due to any cause, whichever came first, assessed up to 120 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * pNETs lesions pathologically classified as WHO grade 2 * Complete surgical resection (R0 or R1 was achieved) * Adjuvant treatment was performed within 12 weeks after surgery Exclusion Criteria: * Stage IV * Other oncological history * Previous antineoplastic systemic therapy * Lack of information/details on recurrence or death.
References
Publications (0)
Data not yet available
No reference posted for this study.